Pictet Asset Management (Switzerland)’s Alnylam Pharmaceuticals ALNY Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$123M	Buy	648,546 +44,471	+7%	+$8.82M	0.15%	176
2023 Q1	$121M	Buy	604,075 +162,513	+37%	+$34.2M	0.15%	177
2022 Q4	$105M	Sell	441,562 -234,247	-35%	-$50M	0.15%	182
2022 Q3	$135M	Sell	675,809 -5,180	-0.8%	-$988K	0.2%	151
2022 Q2	$99.3M	Buy	680,989 +20,049	+3%	+$2.84M	0.14%	201
2022 Q1	$108M	Buy	660,940 +46,948	+8%	+$7.15M	0.12%	207
2021 Q4	$104M	Sell	613,992 -209,712	-25%	-$39M	0.1%	225
2021 Q3	$156M	Buy	+823,704	New	+$155M	0.17%	164

Other funds holding ALNY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s ALNY Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Alnylam Pharmaceuticals (ALNY) stake by 7.4% in Q2 2023, buying an estimated $8.82M and bringing the position to 648,546 shares worth $123M. The position accounts for 0.15% of the portfolio, ranked #176.

Pictet Asset Management (Switzerland) first reported a position in ALNY in Q3 2021 and has held it in 8 quarters since. The position peaked at $156M in Q3 2021. 477 funds tracked by Wall St. Rank hold ALNY as of Q2 2023.

Pictet Asset Management (Switzerland) held 648,546 shares of Alnylam Pharmaceuticals worth $123M as of Q2 2023.
Pictet Asset Management (Switzerland) bought 44,471 Alnylam Pharmaceuticals shares in Q2 2023, an estimated $8.82M.
Alnylam Pharmaceuticals made up 0.15% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #176 holding.
Pictet Asset Management (Switzerland) first reported a position in Alnylam Pharmaceuticals in Q3 2021 and has held it in 8 quarters since.
Pictet Asset Management (Switzerland)'s Alnylam Pharmaceuticals position peaked at $156M in Q3 2021.
477 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.